1992, PhD, University of California, Los Angeles (UCLA), USA
2020 ~ date, CEO, Emerging Infectious Disease Division (EIDD), Biomedical Translation Research Center (BioTReC), Academia Sinica
The increasing prevalence of dengue virus (DENV) infection presents serious disease and economic burden in epidemic countries. Despite the clinical importance, no DENV vaccine or anti-DENV drug is available. In this study, we found that prochlorperazine (PCZ), a dopamine D2 receptor (D2R) antagonist approved to treat nausea, vomiting and headache in humans, has potent in vitro and in vivo antiviral activity against DENV infection.